-
EP4377354
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4377354
| EP4377354 - ANTI-CD33 ANTIBODIES AND USES THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 03.05.2024 Database last updated on 30.10.2024 | |
| Former | The international publication has been made Status updated on 03.02.2023 | Most recent event Tooltip | 03.10.2024 | Change: Validation states | published on 06.11.2024 [2024/45] | 03.10.2024 | Change - extension states | published on 06.11.2024 [2024/45] | Applicant(s) | For all designated states Nanjing Legend Biotech Co., Ltd. No.6 Building of Nanjing Life Science Town No. 568 Longmian Avenue Jiangning District Nanjing, Jiangsu 211100 / CN | [2024/23] | Inventor(s) | 01 /
ZHANG, Yafeng Nanjing, Jiangsu 211100 / CN | 02 /
ZHU, Yanliang Nanjing, Jiangsu 211100 / CN | 03 /
TANG, Wanbing Nanjing, Jiangsu 211100 / CN | 04 /
YANG, Shuai Nanjing, Jiangsu 211100 / CN | 05 /
WU, Shu Nanjing, Jiangsu 211100 / CN | [2024/23] | Representative(s) | Murgitroyd & Company 165-169 Scotland Street Glasgow G5 8PL / GB | [2024/23] | Application number, filing date | 22848722.9 | 01.08.2022 | [2024/23] | WO2022CN109529 | Priority number, date | WO2021CN109827 | 30.07.2021 Original published format: PCT/CN2021/109827 | [2024/23] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2023006118 | Date: | 02.02.2023 | Language: | EN | [2023/05] | Type: | A1 Application with search report | No.: | EP4377354 | Date: | 05.06.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 02.02.2023 takes the place of the publication of the European patent application. | [2024/23] | Search report(s) | International search report - published on: | CN | 02.02.2023 | Classification | IPC: | C07K16/28, A61K39/395 | [2024/23] | CPC: |
C07K16/2803 (EP);
A61K39/001111 (EP);
A61K39/4611 (EP);
A61K39/4631 (EP);
A61K39/464402 (EP);
A61K39/464411 (EP);
A61K39/464429 (EP);
A61P35/02 (EP);
C07K14/7051 (EP);
C07K16/2851 (EP);
A61K2239/29 (EP);
A61K2239/31 (EP);
A61K2239/38 (EP);
C07K2317/22 (EP);
C07K2317/31 (EP);
C07K2317/33 (EP);
C07K2317/565 (EP);
C07K2317/622 (EP);
C07K2317/92 (EP);
C07K2319/00 (EP);
C07K2319/03 (EP);
C12N2740/16043 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/23] | Title | German: | ANTI-CD33-ANTIKÖRPER UND VERWENDUNGEN DAVON | [2024/23] | English: | ANTI-CD33 ANTIBODIES AND USES THEREOF | [2024/23] | French: | ANTICORPS ANTI-CD33 ET LEURS UTILISATIONS | [2024/23] | Entry into regional phase | 23.01.2024 | National basic fee paid | 23.01.2024 | Search fee paid | 23.01.2024 | Designation fee(s) paid | 23.01.2024 | Examination fee paid | Examination procedure | 23.01.2024 | Examination requested [2024/23] | 21.08.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 22.08.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | |||